General description
Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.
INN
Imatinib
Medicine type
Chemical agent
EML status history
First added in 2015
(TRS
994)
for
Chronic myeloid leukaemia, NOS
Added in 2015
(TRS
994)
for
Gastrointestinal stromal tumour of unspecified gastrointestinal sites
Wikipedia
DrugBank
Recommendations
Section
Targeted therapies
- Oral > Solid: 100 mg tablet; 400 mg tablet